FDA Okays First Liquid Form of Antiepileptic Zonisamide

The first oral liquid suspension formulation of the antiepileptic medication zonisamide (Zonisade 100 mg/5 mL) has received approval from the US Food and Drug Administration for use as an adjunctive therapy for partial seizures in adults and adolescents with epilepsy who are 16 years of age or older.

In a press statement announcing the clearance of the new formulation, Richard Blackburn, CEO of Azurity Pharmaceuticals, stated that Zonisade “offers healthcare practitioners an essential new therapy choice for their patients with epilepsy.”

The business stated in the statement that zonisamide has been shown to be effective and tolerable in adults and adolescents in three double-blind, placebo-controlled, multicenter clinical trials.

The capsule form of zonisamide (Zonegran) was initially authorised in the United States in 2000, and generic versions are now accessible. The recently authorised oral suspension of zonisade should be taken once or twice day, with or without food.

Anticonvulsants, often known as antiepileptic medicines, are a broad class of pharmaceuticals used to treat epileptic seizures. Antiepileptic medications function in a variety of ways to suppress or reduce neuronal activation in order to stop seizures from happening. The pathophysiology and classification of seizures, action potentials, excitatory and inhibitory neurotransmission (the function of glutamate and GABA), voltage-gated sodium and calcium channels, AMPA and NMDA receptors, antiepileptic drug mechanisms of action, and side effects are some of the topics covered in this pharmacology lecture. Carbamazepine, Oxcarbazepine, Lamotrigine, Phenytoin, Topiramate, Valproic acid, Zonisamide, Gabapentin, Pregabalin, Levetiracetam, Felbamate, Tiagabine, and Vigabatrin are only a few of the medications mentioned.

Add a Comment

Your email address will not be published.